Multifocal choroiditis and panuveitis

Alumis Announces Expansion of Allosteric TYK2 Inhibitor, ESK-001, Phase 2 Program into Systemic Lupus Erythematosus (SLE) and Uveitis

Retrieved on: 
Thursday, June 29, 2023
Sarcoidosis, Lupus, Week, Eye, Clinical trial, Pharmacokinetics, NIU, Multifocal choroiditis and panuveitis, SLE, Uveitis, Rheumatoid arthritis, Psoriasis, Inflammatory bowel disease, Patient, Uvea, SAN, TYK2, Cytokine, STRIDE, Safety, Disease, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced that patient dosing has commenced in LUMUS, a Phase 2b clinical trial of ESK-001 for the treatment of patients with systemic lupus erythematosus (SLE) and in OPTYK-1, a proof-of-concept Phase 2 clinical trial in uveitis. SLE is a chronic immune-mediated disease involving multiple organs. ESK-001 is Alumis’ proprietary lead clinical candidate and is a highly selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor.

Key Points: 
  • ESK-001 is Alumis’ proprietary lead clinical candidate and is a highly selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor.
  • “ESK-001 is a highly selective allosteric inhibitor of TYK2 that demonstrated full, sustained target inhibition and was well tolerated in Phase 1 studies of healthy volunteers.
  • British-Isles Lupus Assessment Group (BILAG)-based Combined Lupus Assessment (BICLA) is an accepted composite measure of overall SLE disease activity.
  • Alumis continues to leverage its precision data analytics and a multi-platform approach to explore ESK-001’s potential application in other autoimmune indications.

Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection

Retrieved on: 
Tuesday, November 22, 2022
Autoimmunity, Marketing, Bamlanivimab/etesevimab, Macular edema, EUA, Rheumatism, Severe acute respiratory syndrome coronavirus 2, NMPA, Junshi, B cell, Inflammatory bowel disease, Incidence, TNF, Prevalence, Microbiology, Patient, IBD, Rheumatoid arthritis, HKEX, Ulcerative colitis, Cataract, UC, FDA, Multifocal choroiditis and panuveitis, COVID-19, Adalimumab, SSE, Glaucoma, Cancer, Ankylosing spondylitis, Lilly, Inflammation, Retinopathy, Social responsibility, Severe cognitive impairment, Juvenile idiopathic arthritis, National Medical Products Administration, Degenerative disease, Macrophage, Bamlanivimab, Infection, Quality of life, Psoriasis, Uveitis, Pharmaceutical industry, Vaccine, Science, Chinese

is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience Co., Ltd.

Key Points: 
  • is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience Co., Ltd.
  • In March 2022, its indications including rheumatoid arthritis, ankylosing spondylitis and psoriasis were approved by the NMPA.
  • Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China.
  • Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).

Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection

Retrieved on: 
Thursday, August 18, 2022
Psoriasis, GLOBE, Death, EUA, Prevalence, Marketing, Patient, Ulcerative colitis, Glaucoma, National Medical Products Administration, Inflammation, Junshi, IBD, Autoimmunity, Macular edema, Social responsibility, Lilly, B cell, HKEX, NMPA, Safety, SSE, Juvenile idiopathic arthritis, Rheumatoid arthritis, Incidence, Rheumatism, Microbiology, Cancer, COVID-19, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, FDA, Inflammatory bowel disease, Retinopathy, Cataract, UC, Ankylosing spondylitis, Bamlanivimab, Multifocal choroiditis and panuveitis, Quality of life, Company, Infection, TNF, Severe cognitive impairment, Macrophage, Bamlanivimab/etesevimab, Uveitis, Pharmaceutical industry, Vaccine, Chinese, Science

SHANGHAI, China, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the Company has received an Acceptance Notice issued by the National Medical Products Administration (“NMPA”). The supplemental application for additional indications of the company’s adalimumab injection (project code: UBP1211, trade name: 君迈康), including the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children, has been accepted.

Key Points: 
  • The supplemental application for additional indications of the companys adalimumab injection (project code: UBP1211, trade name: ), including the treatment of Crohns disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohns disease in children, has been accepted.
  • is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience Co., Ltd.
  • In March 2022, its indications including rheumatoid arthritis, ankylosing spondylitis and psoriasis were approved by the NMPA.
  • Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc).

Tarsier Pharma announces development of TRS02, a potential immunomodulator, for the treatment of retinal diseases with sustained-release intravitreal formulation

Retrieved on: 
Monday, August 15, 2022
Inflammation, CEO, Glaucoma, Standard of care, Clinical trial, Macular degeneration, Steroid, Multifocal choroiditis and panuveitis, Patient, TEL, Eye, Therapy, Severe cognitive impairment, COO, Safety, TRS, Uveitis, Retina, III, Investigational New Drug, Pharmaceutical industry, IND, Tarsier

It is currently being evaluated in a phase III clinical trial of TRS01 eye drops in patients with non-infectious anterior uveitis & uveitic glaucoma.

Key Points: 
  • It is currently being evaluated in a phase III clinical trial of TRS01 eye drops in patients with non-infectious anterior uveitis & uveitic glaucoma.
  • TRS02 is currently in pre-IND (Investigational New Drug) stage of development and is being further developed towards IND submission.
  • Dr. Daphne Haim-Langford, CEO & Chairperson of Tarsier Pharma, added: "Tarsier is an Ophthalmic company focusing on developing technologies to save sight for patients struggling with blinding diseases.
  • Together with our lead candidate, TRS01 eye drop formulation for front of the eye, TRS02 will enable the treatment of back-of-the-eye devastating diseases."

Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom

Retrieved on: 
Friday, February 4, 2022
Safety, Rheumatoid arthritis, Multifocal choroiditis and panuveitis, Patient, Medication, Immune system, Health care, Intermediate, Eosinophilic esophagitis, Inflammation, Autoimmunity, Degenerative disease, MHRA, Adult, BIP, Revolo, EOE, Severe cognitive impairment, GLOBE, IV, United Kingdom, Pharmaceutical industry, Vaccine, Allergy, Uveitis

Revolo is also enrolling patients in two ongoing Phase 2 studies to evaluate its drug 1104 in Eosinophilic Esophagitis (EoE) under a U.S. IND in Allergic Disease.

Key Points: 
  • Revolo is also enrolling patients in two ongoing Phase 2 studies to evaluate its drug 1104 in Eosinophilic Esophagitis (EoE) under a U.S. IND in Allergic Disease.
  • Revolo Bios Phase 2 trial in RA is a randomized, double-blind, placebo-controlled, dose-escalation study to investigate the effects of 1805 in patients with moderate to severe active RA.
  • 1805 is a modified analogue of a key protein in immune function being evaluated in a second Phase 2 clinical trial for moderate-to-severe rheumatoid arthritis and a Phase 2 clinical trial for non-infectious uveitis.
  • The disease-agnostic mechanism of action of Revolo Biotherapeutics assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases.

Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval

Retrieved on: 
Monday, September 27, 2021
Multifocal choroiditis and panuveitis, UC, Colectomy, Psoriasis, Hematochezia, Crohn's disease, Bechet, Ajinomoto, Adalimumab, Degenerative disease, Abdominal pain, Virology, Gastroenterology, LinkedIn, Adult, Disease, Immune system, Anemia, Twitter, Co-promotion, Ulcerative colitis, Maintenance, Fever, Inflammatory bowel disease, Erosion, Gastrointestinal disease, Patient, Uveitis, Pediatrics, Inflammation, YouTube, Marketing, Eisai, Neurology, Economic cost, Neuroscience, Rheumatoid arthritis, ACCA, Ankylosing spondylitis, Instagram, Diagnosis, Hidradenitis suppurativa, Juvenile idiopathic arthritis, Psoriatic arthritis, Bacteria, Prevalence, Pyoderma, AbbVie, Structural Damage, Pustular psoriasis, Pharmaceutical industry, Medicine, Health insurance, Vaccine, Aluminium, Fine chemical, Dietary supplement

TOKYO, Sept 27, 2021 - (JCN Newswire) - AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients regarding fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA (generic name, adalimumab [recombinant]; "HUMIRA").

Key Points: 
  • TOKYO, Sept 27, 2021 - (JCN Newswire) - AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients regarding fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA (generic name, adalimumab [recombinant]; "HUMIRA").
  • It remains a long-term condition that is not adequately controlled in some patients; more treatment options are needed.
  • The disease rarely develops in childhood, with an estimated prevalence in Japan of 15 per 100,000 between the ages of 0 to 19.
  • HUMIRA is a fully human anti-TNF-alpha monoclonal antibody.

AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Patients"

Retrieved on: 
Monday, September 13, 2021

"Humira Support Tool Ordering Service for Patients" is a free-of-charge service that assists patients on Humira therapy by directly delivering support tools to their home or other requested location.

Key Points: 
  • "Humira Support Tool Ordering Service for Patients" is a free-of-charge service that assists patients on Humira therapy by directly delivering support tools to their home or other requested location.
  • This service is intended to allow patients to shorten the time required to receive support tools and reduce the burden of carrying them.
  • Through providing "Humira Support Tool Ordering Service for Patients," AbbVie, Eisai, and EA Pharma are committed to further enhancing patient support programs and contributing to improved treatment adherence.
  • EA Pharma Co., Ltd., is a gastrointestinal specialty pharmaceutical company with a full value chain covering R&D, production & logistics and sales & marketing.

Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India

Retrieved on: 
Monday, August 16, 2021
Pharming, Choroid, National Medical Products Administration, Macular edema, CEO, ASEAN, Food and Drug Administration, Multifocal choroiditis and panuveitis, Vision, Company, UME, Food, Disease, Severe cognitive impairment, Medicine, Sclera, Retina, IND, NMPA, NDA, FDA, Eye, Patient, Secretary General of the ASEAN, Uveitis, File, Clearside, Nasdaq, Genta (company), Pan-Asia, SCS, Pharmaceutical industry

ARVN001 is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the suprachoroidal space (SCS) through Clearside's patented SCS Microinjector.

Key Points: 
  • ARVN001 is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the suprachoroidal space (SCS) through Clearside's patented SCS Microinjector.
  • In China, Arctic Vision is planning to initiate a Phase III clinical trial in the 2nd half of the year.
  • Dr. Eddy (Hoi Ti) Wu, Founder, CEO and Board Director of Arctic Vision, commented: "We are very excited to expand the license territory of ARVN001 in Asia, as well as our relationship with Clearside.
  • In March 2020, Arctic Vision acquired the exclusive license for the development and commercialization of XIPERE in Greater China and South Korea.

Global Uveitis Epidemiology Forecast Research Report 2021-2029 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 9, 2021
Health, Optical, Sex, Epidemiology, Uveitis, Risk, Man, Degenerative disease, AGR, Inflammation, Doctor of Philosophy, Woman, Multifocal choroiditis and panuveitis, Vaccine, Dietary supplement

The "Uveitis - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Uveitis - Epidemiology Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The Uveitis Epidemiology Report provides an overview of the risk factors and global trends of uveitis in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Australia, and Canada).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of uveitis segmented by sex and age (ages 18 years).
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.